Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory
We came across a bullish thesis on Sellas Life Sciences Group Inc (SLS) on ValueInvestorsClub by ContraMundem. In this article we will summarize the bulls' thesis on SLS.
Sellas Life Sciences Group Inc. (SLS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 0 | $0 | -100% | 0% | |
| 2. | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.94 | 20,000 | Director | 23,500 | 2014-02-07 | Filing | |
| $0.60 | 5,000 | Officer | 5,000 | 2011-12-07 | Filing | |
| $0.66 | 10,000 | Officer, Director | 20,000 | 2011-12-07 | Filing | |
| $0.95 | 10,000 | Officer, Director | 10,000 | 2011-04-20 | Filing | |
| $2.23 | 10,000 | Officer, Director | 15,407 | 2010-07-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.61 | 6,494 | Officer, Director | 161,689 | 2022-12-05 | Filing | |
| $2.59 | 1,159 | Officer | 29,347 | 2022-12-05 | Filing | |
| $2.59 | 2,153 | Officer | 56,344 | 2022-12-05 | Filing | |
| $6.25 | 2,120 | Officer, Director | 121,167 | 2021-12-02 | Filing | |
| $6.25 | 847 | Officer | 42,028 | 2021-12-02 | Filing |
Institutional Investors' Holdings
News See All
Is SELLAS Life Sciences Group, Inc. (SLS) A Good Stock To Buy Now?
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Market Movers Today: Alnylam Pharmaceuticals, Inc. (ALNY), Snap Inc (SNAP), Sellas Life Sciences Group Inc (SLS), Intel Corporation (INTC), and More
What happened: Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a precommercial pioneer of RNA-based therapies, continued a slide that began just ahead of the weekend.
13G Filing: Sabby Capital and Sellas Life Sciences Group Inc. (SLS)
Sabby Healthcare Master Fund, Ltd | 0 | 92,202 | 0 | 92,202 | 92,202 | 6.05 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 81642T100 1.
Billionaire Hedge Funds
